Related Experiment Video
Updated: Jun 1, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Drug discovery for polycystic kidney disease
Ying Sun1, Hong Zhou, Bao-xue Yang
1Department of Pharmacology, School of Basic Medical Sciences, Peking University, and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing 100191, China.
Abstract:
In polycystic kidney disease (PKD), a most common human genetic diseases, fluid-filled cysts displace normal renal tubules and cause end-stage renal failure. PKD is a serious and costly disorder. There is no available therapy that prevents or slows down the cystogenesis and cyst expansion in PKD. Numerous efforts have been made to find drug targets and the candidate drugs to treat PKD. Recent studies have defined the mechanisms underlying PKD and new therapies directed toward them. In this review article, we summarize the pathogenesis of PKD, possible drug targets, available PKD models for screening and evaluating new drugs as well as candidate drugs that are being developed.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Drug Discovery: Overview
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Diabetic Nephropathy

